Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
TXG Catalyst Timeline
Dated clinical, regulatory and corporate events for 10x Genomics, Inc.
Past FDA Catalysts and PDUFA Decisions
How TXG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
10x Genomics, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TXG program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Saxonov SergeDirector, Officer (Chief Executive Officer) | Sell | -31,000 1,019,249 held | $62.90 | 11/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TXG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 2 % (-45.9 %) | 40.26 M | 1.05 M | -53.85% ( -1.23 M) |
Ownership Trends
TXG Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How TXG ranks across every disease it competes in
TXG News
Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform
10x Genomics announced a 24-month study in collaboration with Fudan University Shanghai Cancer Center and Shanghai Precision Diagnostics. The study aims to identify biomarkers that predict breast cancer patients' responses to neoadjuvant therapy. It will analyze tumor biopsy samples from 500 patients using the Xenium platform to enhance treatment personalization.
Read more →10x Genomics Reports Third Quarter 2026 Financial Results
10x Genomics reported a revenue of $150.7 million for Q3 2026, marking a 1% increase from the previous year. The company successfully launched Atera, which has seen strong demand. Despite a gross margin improvement to 75%, 10x Genomics reported an operating loss of $16.1 million and a net loss of $19.4 million.
Read more →10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis
10x Genomics launched Sentira Single Cell, a cloud-based AI application for analyzing Chromium data. This tool allows researchers to use natural language for inquiries, streamlining the path from questions to conclusions. Built on 10x Cloud, it offers scalable computing power and promotes independent data exploration. The application aims to democratize single cell research.
Read more →10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference
10x Genomics announced its participation in the 2026 Jefferies Global Healthcare Conference. The management team will engage in a fireside chat on November 17 at 4:30 p.m. GMT. Interested parties can access a live webcast on the company's website, which will be available for replay for 30 days.
Read more →10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
10x Genomics, a leader in life science technology, will announce its third quarter financial results on November 5, 2026. The company will hold a public conference call to discuss these results and its business outlook. The financial results will be available on their website before the call, which will also be archived for later access.
Read more →10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
10x Genomics has announced a collaboration with Fred Hutch Cancer Center to enhance single cell and spatial technologies in cancer research. This initiative will focus on bladder cancer and acute myeloid leukemia, aiming to improve treatment response analysis and biomarker discovery. The partnership represents a significant step towards precision oncology.
Read more →10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
10x Genomics has launched Sentira, a new cloud analysis platform aimed at streamlining the analysis of complex biological data. The platform, starting with Sentira Spatial Analysis, significantly reduces data processing times, enabling researchers to reach experimental conclusions more rapidly. This innovation is expected to enhance the capabilities of researchers in spatial biology, especially with the integration of NVIDIA's accelerated computing.
Read more →10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands
10x Genomics has commenced global shipments of its Atera platform, which integrates advanced spatial biology capabilities. This innovative tool allows researchers to conduct comprehensive studies across various disease areas, including oncology and neurodegenerative diseases. The initial response has been overwhelmingly positive, with significant demand from leading research institutions and biopharma companies. Atera aims to transform biological research and drug discovery.
Read more →10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
10x Genomics won a patent infringement case against Parse Biosciences, with a jury ruling that Parse willfully infringed three patents licensed to Scale Biosciences. The jury awarded over $4.8 million in damages and rejected Parse's validity challenges. This decision underscores the significance of patent rights in fostering innovation in the life sciences sector.
Read more →10x Genomics Reports Second Quarter 2026 Financial Results
10x Genomics reported its second quarter 2026 financial results, revealing a revenue of $151 million, a 3% increase when excluding non-recurring revenue. The company acquired Proteintech Genomics to enhance its capabilities and announced collaborations with major research institutions. However, it faced an operating loss of $19.6 million and a net loss of $17.9 million, highlighting challenges despite revenue growth.
Read more →10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
10x Genomics has partnered with Lausanne University Hospital to enhance cancer diagnostics using single cell and spatial technologies. The collaboration aims to identify biomarkers that predict treatment responses across various cancer types. This multi-year study will analyze tumor samples from patients and integrate clinical outcomes to improve personalized treatment strategies.
Read more →10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
10x Genomics, a leader in life science technology, will report its second quarter 2026 financial results on August 6, 2026. The report will be followed by a public conference call at 1:30 PM PT to discuss the results and future outlook. The financial results will be available on the company's website prior to the call.
Read more →10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
10x Genomics has partnered with Cleveland Clinic to enhance diagnostic research for bladder cancer. This multi-year collaboration will utilize 10x's advanced platforms to analyze tumor samples from patients undergoing new therapies. The goal is to identify biomarkers that predict patient responses, improving treatment personalization in oncology.
Read more →10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
10x Genomics has acquired Proteintech Genomics to enhance its proteomics capabilities. This acquisition introduces the Human Discovery Panel, which allows integrated analysis of proteins and transcriptomic profiles. The move aligns with 10x's vision of advancing multiomic approaches in biological research. The transaction is not expected to significantly impact 10x's near-term financial outlook.
Read more →10x Genomics Reports First Quarter 2026 Financial Results
10x Genomics reported its first quarter 2026 financial results, showing a 3% decrease in revenue to $150.8 million. However, excluding one-time revenues from the previous year, revenue increased by 9%. The company launched Atera, a new platform for spatial whole-transcriptome analysis, and ended the quarter with $539.8 million in cash. Despite a net loss of $13.5 million, the company remains optimistic about its growth trajectory.
Read more →10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference
10x Genomics, a leader in single cell and spatial biology, will participate in the BofA Securities 2026 Healthcare Conference on May 13. The management team will engage in a fireside chat, which will be available via a live webcast. This event highlights the company's commitment to advancing human health through innovative research solutions.
Read more →10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
10x Genomics has launched Atera, a new platform for whole-transcriptome spatial biology analysis, offering single-cell sensitivity at scale. Debuting at the AACR Annual Meeting 2026, Atera aims to redefine biological measurement by overcoming previous limitations in spatial technologies. The platform has garnered interest from major research institutions and is expected to enhance understanding of complex biological systems.
Read more →10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026
10x Genomics, a leader in single cell and spatial biology, will report its financial results for Q1 2026 on May 7, 2026. The company plans to hold a public conference call to discuss these results and future business developments. The financial news release will be available on their website prior to the call.
Read more →PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
10x Genomics has partnered with PharosAI to develop a comprehensive multimodal cancer dataset using AI and spatial biology. This initiative, supported by UK government funding, aims to enhance early diagnosis and precision therapies. The collaboration will initially focus on breast cancer, expanding to other types, and will make datasets accessible to researchers globally.
Read more →10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
10x Genomics, a leader in single cell and spatial biology, will report its financial results for Q4 and the full year 2025 on February 12, 2026. The announcement includes a public conference call for analysts and investors to discuss the results and future outlook. The financial results will be available on the company's website prior to the call.
Read more →